Tirzepatide
Synergistic appetite suppression and insulin modulation via two incretin pathways.
SC injection (abdomen) — 5 mg weekly SC as a typical starting protocol (per "Metabolic Reset Archetype"); titrated to 10–15 mg weekly; available in 10 mg and 40 mg dose vials
What It Is
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that engages both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, providing synergistic appetite suppression and insulin modulation via two incretin pathways.
Mechanism
Tirzepatide engages both GLP-1 and GIP receptors — providing synergistic appetite suppression and insulin modulation via two incretin pathways. In trials, combining a GLP-1 analog with cagrilintide (an amylin analog in the cagrisema combination) led to unprecedented weight loss (~20% body weight in 68 weeks). Tirzepatide directly targets fat cells to increase lipolysis without IGF-1 side effects. Its dual mechanism curbs appetite through multiple brain pathways.
How Dr. Emer Uses It
In Emer's Chronic Metabolic Offset protocol, a GLP-1 agonist (low-dose) is combined with AOD-9604 (to target stubborn fat deposits) and sometimes tesofensine or 1-MQ if appetite or metabolism needs further push. In the "50-Year-Old Male, Metabolic Reset Archetype," Tirzepatide (5 mg weekly) is the anchor for potent weight loss and glycemic control. Long-term, select patients remain on a rotation of GLP-1 or tirzepatide as part of their chronic wellness stack to maintain lower visceral adiposity.
Key Benefits
- ✓Dual GIP/GLP-1 agonism for synergistic appetite suppression via two incretin pathways
- ✓Superior weight loss efficacy vs semaglutide alone in clinical comparisons
- ✓Directly targets fat cells to increase lipolysis without IGF-1 side effects
- ✓Improves insulin sensitivity and reduces systemic inflammation
- ✓Pre-surgical metabolic prehabilitation for visceral fat and liver fat reduction
- ✓Maintenance of lower visceral adiposity in chronic wellness programs
Pairs Well With
Used In Programs
Safety & Considerations
Common side effects are gastrointestinal — notably nausea, early satiety, bloating, reflux, sometimes vomiting or constipation. These typically peak during dose uptitration. Slower titration and adjuncts (e.g. antiemetic supplements, hydration IVs) mitigate these effects. Serious but rare risks include pancreatitis, gallbladder stasis, and thyroid C-cell tumor warning (same as GLP-1 class — avoid in personal/family history of medullary thyroid carcinoma or MEN2). Monitoring includes weekly weight, glucose trends, and symptom logs.
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
